title: Intralesional rituximab for primary iris lymphoma.
authors.affiliation: Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, University of Michigan, Ann Arbor.
authors.forename: Hakan
authors.initials: H
authors.lastname: Demirci
authors.affiliation: Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, University of Michigan, Ann Arbor.
authors.forename: Joshua S
authors.initials: JS
authors.lastname: Grant
authors.affiliation: Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, University of Michigan, Ann Arbor.
authors.forename: Victor M
authors.initials: VM
authors.lastname: Elner
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D015552:Injections, Intralesional; D015811:Iris Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D018442:Lymphoma, B-Cell, Marginal Zone / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D033401:Microscopy, Acoustic; D008875:Middle Aged; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab